Drug Profile
Research programme: cancer and metabolic disorder therapeutics - Luye Pharma Group
Alternative Names: LY 01611; TS 0802; TS 0901; TS 0903; TS 0904; TS 0963Latest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Luye Pharma Group
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Metabolic disorders
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for preclinical development in Cancer in China
- 28 Jan 2018 No recent reports of development identified for research development in Metabolic-disorders in China
- 01 Dec 2013 Early research in Metabolic disorders in China prior to December 2013 (Luye Pharma Website)